Data suggests that people with MS treated with cladribine are able to mount a protective immune response after influenza and varicella zoster vaccination regardless of the timing of the vaccine relative to the cladribine dose and independent of lymphocyte counts. Real-world data has also shown that cladribine does not impair the humoral response to COVID-19 vaccination.

In this podcast Professor Klaus Schmierer, Professor of Neurology at Queen Mary University of London and Royal London Hospital, UK, discusses how this data informs the management of patients during the pandemic.

This podcast was sponsored by Merck Healthcare. Views and opinions expressed in this presentation are those of the presenter alone. The information is not medical advice, and no decision relating to the management of any patient should be made with reliance on the information contained in the presentation. It’s your responsibility to prescribe appropriate treatments in accordance with your clinical judgment and by reference to the appropriate Australian product information or other information supplied with the relevant product, including in relation to any indication dosage and route of administration.